NOVOMEDLINK™
  1. Activella®

    (estradiol/norethindrone acetate tablets)

  2. Vagifem®

    (estradiol vaginal tablets)

  3. GlucaGen® HypoKit®

    (glucagon [rDNA Origin] for injection)

  4. Levemir®

    (insulin detemir [rDNA origin] injection)

  5. Norditropin®

    (somatropin (rDNA origin) injection)

  6. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  7. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  8. NovoSeven® RT

    Coagulation Factor VIIa (Recombinant) Room
    Temperature Stable

  9. NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

Efficacy and Proven Safety From the Start41

Majority of patients got to goal with NovoLog® Mix 70/3041

A recent study evaluated two approaches for initiating insulin in patients with type 2 diabetes who were not reaching target glycemic goals.41 One group of patients received BID NovoLog® Mix 70/30 and the other received a QD basal insulin analog.

As the chart below demonstrates, initiating BID NovoLog® Mix 70/30 provided significantly improved glycemic control compared with a QD basal analog.

Additionally, NovoLog® Mix 70/30 reduced FPG and lowered mean dinner PPG excursion. It is important to note that metformin was optimized in both arms and pioglitazone (TZD) was continued for all patients who were taking a TZD prior to trial.41

Low rate of hypoglycemia41

It is important to note that there were no major hypoglycemic events in this study.41

Multicenter, randomized, open-label, parallel-group, treat-to-target, 24-week trial in 233 patients with type 2 diabetes taking twice-daily NovoLog® Mix 70/30 or a QD basal analog. A 4-week metformin optimization period with or without TZDs preceded randomization. All patients continued metformin therapy throughout the trial; pioglitazone therapy was continued by patients taking pioglitazone or rosiglitazone before trial initiation. Intent-to-treat population — NovoLog® Mix 70/30, n=108; basal analog, n=114.

Additionally, the overall rate of minor hypoglycemia for patients taking NovoLog® Mix 70/30 was 3.4 episodes per patient-year.41

  1. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Indications and Usage

    NovoLog® Mix 70/30 is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia.

    NovoLog® Mix 70/30 Important Safety Information

    NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients.

    Because NovoLog® Mix 70/30 has peak pharmacodynamic activity 1 hour after injection, it should be administered with meals. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog® Mix 70/30. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, species, or method of manufacture may result in the need for a change in dosage. Potential side effects associated with the use of all insulins include hypoglycemia, hypokalemia, lipodystrophy, and allergic reactions.

    Because of differences in the action of NovoLog® Mix 70/30 and other insulins, care should be taken in patients in whom these conditions may be clinically relevant (eg, patients who are fasting, have autonomic neuropathy, are using potassium-lowering drugs, or are taking drugs sensitive to serum potassium level). Do not mix NovoLog® Mix 70/30 with any other insulin product.

    As with other insulin therapy, erythema, swelling, and pruritus at the injection site have been observed with NovoLog® Mix 70/30. Less common but more serious are severe cases of generalized allergy, including anaphylactic reaction, which may be life threatening. NovoLog® Mix 70/30 dose requirements may be reduced in the presence of renal impairment or impaired hepatic function. Changes in cross-reactive antibodies were more common after NovoLog® Mix 70/30 than with human premixed 70/30, but the clinical significance of these antibodies has not been established. Frequency of adverse events comparable with that of human 70/30. Local injection site reactions comparable with those of human 70/30.

    Please see Prescribing Information.

Levemir®, NovoLog®, NovoLog® Mix 70/30, GlucaGen®, HypoKit®, and FlexPen® are registered trademarks of Novo Nordisk A/S. NovoSeven® RT and Norditropin® are registered trademarks of Novo Nordisk Health Care AG. Activella® 1.0 mg/0.5 mg, Activella® 0.5 mg/0.1 mg, and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.